No acquisition but Roche/Chugai rejig alliance terms
This article was originally published in Scrip
After rumors of a planned Roche buy-out of Chugai failed to materialize, the two companies have instead restructured some of the key terms of their original 2001 strategic alliance, in a change that will give Roche broader access and rights to Chugai's pipeline.
You may also be interested in...
While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.